Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
80.74
-1.18 (-1.44%)
At close: Jul 24, 2026, 4:00 PM EDT
80.50
-0.24 (-0.29%)
After-hours: Jul 24, 2026, 7:39 PM EDT

Cytokinetics Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, Cytokinetics stock has a consensus rating of "Buy" and an average price target of $107.8. The average 1-year stock price forecast is 33.51% higher than the current stock price, while the lowest is $83 (+2.80%) and the highest is $146 (+80.83%).

Price Target: $107.8 (+33.51%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$83$107.8$105$146
Change+2.80%+33.51%+30.05%+80.83%

Analyst Ratings

The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy101011121313
Buy777777
Hold333322
Sell000000
Strong Sell000000
Total202021222222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Buy
Reiterates
$103
BuyReiterates$103+27.57%Jul 23, 2026
Bank of America Securities
Bank of America Securities
Hold
Maintains
$83
HoldMaintains$83+2.80%Jul 22, 2026
Citi
Citi
Buy
Maintains
$99
BuyMaintains$99+22.62%Jul 16, 2026
RBC Capital
RBC Capital
Buy
Maintains
$119$117
BuyMaintains$119$117+44.91%Jul 7, 2026
UBS
UBS
Buy
Upgrades
$115
BuyUpgrades$115+42.43%Jun 29, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
112.87M
from 88.04M
Increased by 28.20%
Revenue Next Year
393.39M
from 112.87M
Increased by 248.53%
EPS This Year
-6.32
from -6.54
EPS Next Year
-4.68
from -6.32
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
70.43M94.59M7.53M18.47M88.04M112.87M
Revenue Growth
26.15%34.31%-92.04%145.34%376.56%28.20%
Operating Income
-186.31M-324.20M-496.21M-536.25M-612.26M-745.06M
Net Income
-215.31M-388.96M-526.24M-589.53M-784.96M-797.39M
EPS
-----6.54-6.32
Free Cash Flow
-179.83M-127.01M-260.37M-241.29M-379.62M-661.35M
No. Analysts
-----21
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High193.8M
Avg112.9M
Low76.7M

Revenue Growth

Revenue Growth202620272028
High
120.1%
Avg
28.2%
Low
-12.9%

EPS Forecast

EPS202620272028
High-4.80
Avg-6.32
Low-7.47

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-